As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
BUSINESS
Kaken Set to Take Stab at US Market with Vascular Malformation Drug
Kaken Pharmaceutical aims to branch out into the US market now that it has successfully clinched a major out-licensing deal ahead of schedule, with its drug discovery work producing favorable results, President Hiroyuki Horiuchi says. “We’re now at a point…
To read the full story
Related Article
- Kaken Closes US$103 Million Acquisition of Aadi Subsidiary
March 28, 2025
- J&J Bags Kaken’s STAT6 Inhibitor, Set to Take 6% Stake in Japan Firm
December 27, 2024
- Kaken to Snatch Up Aadi Subsidiary for US$100 Million to Establish Global Footprint
December 23, 2024
BUSINESS
- Nxera to No Longer Invest in Non-Priority Assets, Shifts 80% of Pipeline to Obesity and Metabolic Areas
November 19, 2025
- Chugai to Absorb Renalys Pharma in Late December
November 19, 2025
- Nxera Unveils Restructuring Plan to Return to Profit, 15% Job Cuts in Japan and UK
November 18, 2025
- Vital KSK to Repurpose Shield’s Iron Deficiency Drug for PAH in Japan
November 18, 2025
- Lundbeck Files Anti-CGRP Antibody Eptinezumab in Japan
November 18, 2025
Japan is set to tighten reimbursement rules for regenerative medicine products granted conditional, time-limited approval, with Central Social Insurance Medical…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…